Neurocrine Biosciences | NBIX - Trade Debtors

Stock Price
141.78
Daily Change
3.85 2.79%
Monthly
0.82%
Yearly
15.63%
Q1 Forecast
131.87

Neurocrine Biosciences reported $728M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Acadia Pharmaceuticals USD 139.44M 19.75M Sep/2025
Agios Pharmaceuticals USD 5.03M 43K Sep/2025
ALKERMES USD 355.11M 1.22M Sep/2025
Alnylam Pharmaceuticals USD 964.77M 397.66M Sep/2025
Amgen USD 8.49B 211M Sep/2025
Biogen USD 1.85B 234M Sep/2025
BioMarin Pharmaceutical USD 790.27M 65.59M Sep/2025
Cytokinetics USD 1.81M 6.6M Sep/2025
Dynavax Technologies USD 73.34M 16.79M Jun/2025
Exelixis USD 311.3M 17.42M Sep/2025
Gilead Sciences USD 5.1B 314M Sep/2025
Halozyme Therapeutics USD 346.04M 29.7M Sep/2025
Incyte USD 895.89M 53M Sep/2025
Ionis Pharmaceuticals USD 24.61M 27.97M Sep/2025
Neurocrine Biosciences USD 728M 132.3M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
Prothena USD 5.16M 0 Dec/2023
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Repligen USD 148.97M 7.98M Sep/2025
Sarepta Therapeutics USD 395.74M 213.86M Sep/2025
Teva Pharmaceutical Industries USD 3.71B 101M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vertex Pharmaceuticals USD 1.95B 52.9M Sep/2025